Xilio Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XLO research report →
Range $16 – $16
Price Chart
About the company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors.
- CEO
- Rene Russo
- IPO
- 2021
- Employees
- 76
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on XLO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $53.40M
- P/E
- -29.48
- PEG
- -0.07
- P/S
- 0.95
- P/B
- 2.13
- EV/EBITDA
- 6.31
- Div Yield
- 0.00%
- Gross Margin
- 99.37%
- Op Margin
- -74.87%
- Net Margin
- -20.89%
- ROE
- -18.51%
- ROIC
- -37.61%
Latest fiscal year · YoY change
- Revenue
- $43.77M+589.9%
- Gross Profit
- $42.23M+565.6%
- Op Income
- $-41,982,000
- Net Income
- $-35,036,000+39.8%
- EPS
- $-4.19+72.5%
- OCF Growth
- +72.8%
- FCF Growth
- +70.1%
- 52W High
- $10.71
- 52W Low
- $6.47
- 50D MA
- $8.58
- 200D MA
- $8.48
- Beta
- -0.11
- RSI (14)
- 35
- Avg Volume
- 11.31K
No earnings-call transcripts are available for XLO yet.
- Free Float
- 35.2%
- Shares Outstanding
- 7.06M
- Float Shares
- 2.49M
of shares held by institutions
26 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.26M | 0 |
| Bain Capital Life Sciences Investors, LLC | 664.02K | 0 |
| Orbimed Advisors LLC | 592.30K | ▲ 592.30K |
| Frazier Life Sciences Management, L.P. | 422.50K | 0 |
| Vanguard Capital Management LLC | 198.18K | ▲ 19.66K |
| Stonepine Capital Management, LLC | 189.09K | ▼ 36.90K |
| Sio Capital Management, LLC | 152.46K | 0 |
| Adage Capital Partners Gp, L.L.C. | 111.54K | ▲ 111.54K |
| Merck & Co., Inc. | 105.98K | 0 |
| Renaissance Technologies LLC | 63.55K | ▼ 600 |
| Morgan Stanley | 53.67K | ▼ 3.28K |
| Aju Ib Investment Co., Ltd. | 47.70K | ▼ 620.05K |
Held by 25 ETFs
Biggest fund positions in XLO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Houvras Yariv | other | 105,000 |
| Sep 28, 26 | Houvras Yariv | other | 0 |
| Jun 11, 26 | Bello Akintunde Olatokumbo | other | 5,000 |
| Jun 11, 26 | Shannon James Samuel | other | 5,000 |
| Jun 11, 26 | Curran Daniel J. | other | 5,000 |
| Jun 11, 26 | Xu Yuan | other | 5,000 |
| Jun 11, 26 | ROSS ROBERT W. | other | 5,000 |
| Jun 11, 26 | Bonstein Sara | other | 5,000 |
| Jun 11, 26 | Brennan Aoife | other | 5,000 |
| Apr 15, 26 | Blanchard Cheryl R | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XLO coverage
Recent articles, reports, and earnings notes.
No research on XLO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XLO report →Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
globenewswire.com · Nov 10
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
globenewswire.com · Nov 3
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
globenewswire.com · Oct 26
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Xilio Therapeutics Appoints Yariv J. Houvras, M.D.
globenewswire.com · Sep 28
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 2
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
globenewswire.com · Aug 12
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.